哈佛生物科學 HBIO 深 滬
已收盤 10-24 16:00:00 美东时间
0.4079
+0.004
+1.02%
華盛通- 最 高0.4162
- 今 開0.4004
- 成交量 55.03万股
- 最 低 0.4001
- 昨 收 0.4038
- 總市值 1816.43万
- 52周最高 2.82
- 市盈率 靜 --
- 換手率 1.24%
- 52周最低 0.2813
- 委 比 -1.96%
- 總股本 4453.12万
- 歷史最高 8.75
- 量 比 0.79
- 振 幅 3.99%
- 歷史最低 0.2813
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harvard Bioscience Granted 180 Days Or Until March 30, 2026 By Nasdaq For Compliance
- SEC Filing
10-03 20:05
Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
Harvard Bioscience expands its distribution agreement with Fisher Scientific in the U.S., enhancing access to its lab equipment, including pumps, spectrophotometers, and BTX electroporation systems. This collaboration leverages Fisher Scientific’s extensive network and reputation, providing customers with streamlined ordering, faster delivery, and localized support. The expanded agreement simplifies procurement and ensures greater availability of...
09-16 11:00
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.
09-10 20:24
Harvard Bioscience Appoints Stephen DeNelsky to Board
Harvard Bioscience ( ($HBIO) ) just unveiled an update. On September 5, 2025, H...
09-09 19:29
Harvard Bioscience Offers CFO $100K Retention Bonus
An update from Harvard Bioscience ( ($HBIO) ) is now available. On August 12, 2...
08-14 05:03
Harvard Bioscience Amends Credit Agreement with Lenders
Harvard Bioscience ( ($HBIO) ) has shared an update. On August 8, 2025, Harvard...
08-12 05:05
Harvard Bioscience Enters Sixth Amendment To Credit Agreement; Lenders Agree Not To Test Financial Covenants For Q3 2025; Agrees To Pay $400K Fees To Lenders; Explores Alternative Capital Sources For Refinancing; Says There Is Substantial Doubt About Co's Ability To Continue As A Going Concern
Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2025, Harvard Bioscience, Inc. (the "Company") entered into a Sixth Amendment (the "Sixth Amendment") to the Credit Agreement, dated as of December
08-12 04:41
Harvard Bioscience Sees Q3 Sales $19.000M-$21.000M vs $21.75M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $19.000 million-$21.000 million vs $21.75 million analyst estimate.
08-11 19:07
